Trump did keep to GOP health orthodoxy with his push to reimburse insurers for cost-sharing reductions, which insurers must give to low-income Obamacare consumers to pay down out-of-pocket costs like ...

The company’s latest preview report projects a guarded rebound for biopharma, as investor confidence returns and M&A activity ...

At the J.P. Morgan Healthcare Conference, Nvidia announced major AI partnerships with Lilly and Thermo Fisher Scientific to ...

Lawsuit alleges anti-competitive conduct designed to suppress lawful compounding pharmaceuticals and limit patient choice ...

Eli Lilly (LLY) stock slips as the FDA decision on the company's obesity pill orforglipron is now due in April, which ...

The repeat problems at Houston-based Empower Pharmacy include inadequate quality testing and a failure to clean equipment.

Compounding pharmacy sues Eli Lilly and Novo Nordisk alleging antitrust violations to restrict compounded GLP-1 medication access and limit competition.

Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel targets.

Strive Compounding Pharmacy alleged in its lawsuit that Eli Lilly and Novo Nordisk have worked to lock telehealth providers ...

The FDA delayed reviews of two drugs chosen for the Trump administration's new fast-track program after agency scientists ...

Eli Lilly highlighted 2025 as the rollout year for obesity drugs, with Mounjaro at the forefront of its weight-loss portfolio ...